ClinicalTrials.gg
RecruitingNCT07022535PRESELECT-0Updated Jul 2, 2025

Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer

A Phase 2 interventional study of KELIM and Carboplatin plus Paclitaxel in Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer, sponsored by The University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-02.

Sponsored by The University of Hong Kong · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 1 year after the study started (first participant enrolled May 2024, registered Jun 2025).
  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 166 studies testing carboplatin in Ovarian Neoplasms — 14 open to participants now, 21 under way, 6 of them phase 3. Carboplatin · Ovarian Neoplasms.

Planned enrollment
120th of 150
18 · median 48
Started
2024
with 3 others
Phase 2
84 of 166
8 open now
Primary completion
2025-12
later than 6 of 20 live
Registered
162nd of 166
by date

Among the 166 studies testing carboplatin in Ovarian Neoplasms, this one is the 120th largest by planned enrollment of the 150 interventional ones that give a count, is one of 4 that started in 2024, is one of 84 in phase 2, reaches primary completion later than 6 of the 20 other live ones, and was the 162nd registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

14 of the 166 studies testing carboplatin in Ovarian Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 166 studies testing carboplatin in Ovarian Neoplasms, or all of them as a file.
02

Study summary

About 70% of epithelial ovarian cancer patients are diagnosed at advanced stage. When primary optimal surgery is not possible, neoadjuvant chemotherapy will followed by interval debulking surgery is one treatment option. However, there is no consensus on the optimal timing of the surgery. CA125 is a well-known tumor marker in ovarian cancer. Its kinetic change has been proven to correlate with the patients' response to chemotherapy and chance of optimal resection. This study aims to utilize the kinetic change of CA125 to customize the timing of surgery for individual patients.

Read the detailed description

Recruited patients will have additional CA125 at 4th (before administration of chemotherapy), and 5th week after the first cycle of chemotherapy. CA-125 ELIMination Rate Constant K (KELIM) will be determined. Patients with KELIM =>1 will receive radiological assessment and undergo internal debulking surgery if the disease is operable. Patients with KELIM \<1 will have alternative management, such as addition of bevacizumab or changing to dose-dense chemotherapy, and defer the interval debulking surgery

03

Conditions studied

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Peritoneal Cancer

Keywords

  • advanced
  • ovarian cancer
  • neoadjuvant chemotherapy
  • interval debulking surgery
  • KELIM
  • CA 125
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must be at least 18 years old.
  2. Patients who have (ECOG) score 0-1.
  3. Patients who are competent to give .
  4. Patients who have stage III-IV or cytologically confirmed epithelial ovarian cancer, fallopian tube or primary peritoneal cancer not amenable for primary debulking surgery (PDS).
  5. Patients who are planned for chemotherapy (NACT) using platinum-based chemotherapy +/- bevacizumab or biosimilar. Those who are receiving NACT before interval debulking surgery (IDS) are also eligible.
  6. Patients who have an evaluable CA125 level at baseline (i.e., baseline level is at least 2x ).
  7. Patients who have baseline computed tomography of at least abdomen and pelvis, or positron emission tomography (PET)-CT. Magnetic resonance imaging (MRI) is also acceptable but the same modality has to be used when assessing the feasibility of IDS.
  8. Patients who agree to undergo IDS, where the time of IDS may differ from the usual clinical practice.
  9. Patients who agree to receive adjuvant chemotherapy, if clinically indicated. The total number of chemotherapy should be at least four or above.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have borderline , or non-epithelial ovarian cancer like germ cell or sex cord tumor, or diseases from other origins like Krukenberg's tumor
  2. Patients who are eligible for PDS
  3. Patients who are not fit for PDS because of medical morbidities or refusal of operation
  4. Patients who have already started NACT outside the study centres, except those who have just had one cycle within 21 days and the baseline CA125 is available.
  5. Patients who are pregnant
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Personalised management

    Patients will be managed based on CA-125 ELIMination Rate Constant K (KELIM) at the neoadjuvant setting.

    Diagnostic Test: KELIM · Drug: Carboplatin plus Paclitaxel · Procedure: Interval debulking surgery

Interventions

  • Diagnostic testKELIM

    (i) Patients with KELIM \>=1 will receive radiological assessment and undergo interval debulking surgery if the disease is operable. (ii) Patients with KELIM \<1 will have alternative management, such as addition of bevacizumab or changing to dose-dense chemotherapy, and defer the interval debulking surgery

  • DrugCarboplatin plus Paclitaxel

    Drug pages: CarboplatinStudies of CarboplatinCarboplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Chemotherapy as neaodjuvant chemotherapy

  • ProcedureInterval debulking surgery

    Interval debulking surgery

    Also known as: cytoreductive surgery

06

What researchers measure

Primary outcomes

  1. Complete resection (CC0) rate

    The likelihood of CC0 in patients who undergo IDS when KELIM reaches 1 or above

    Time frame: Up to 24 months

  2. Sensitivity of KELIM in predicting CC0

    The sensitivity of KELIM in predicting CC0

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Time required to achieve KELIM >=1

    The time required for KELIM to reach \>=1 in EOC patients receiving NACT

    Time frame: Up to 24 weeks

  2. Complication rates of treatment

    The complication rates of surgery based on the Clavien-Dindo classification and chemotherapy based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)

    Time frame: Up to 1 year

  3. Quality-of-life scale

    Different functional scales will be assessed by questionnaires like the EORTC questionnaires where all scales range from 0-100. The higher the score, the greater the intensity of that particular item is.

    Time frame: Up to 1 year

Other outcomes

  1. Expression of biomarkers

    Expression levels of biomarkers before and after chemotherapy

    Time frame: Up to 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Patients' disease course based on this novel management algorithm

Supporting information: Study protocol

Time frame: One year after the end of the study

Access criteria: The study protocol will be available under a reasonable request to the corresponding author

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2025, 19 months after the start.

Of 229 non-industry phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 80. This study's planned 19 months is below that.

Counting every sponsor, half of 345 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2025
First posted
Jun 15, 2025
StartActual
May 28, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Jul 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07022535
Responsible party
Dr. Ka-Yu Tse (Prof., The University of Hong Kong) — Principal investigator
First posted
Jun 15, 2025
Start date
May 28, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jul 2, 2025

Study contacts

Lesley Lau, MPhil
Contact
lsk382@hku.hk
+852 22554265
Iris Tang
Contact
iristwk@hku.hk
+852 22554265
Ka Yu Tse, MBBS, MMedSc, PhD, FRCOG
principal investigator · The University of Hong Kong

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carboplatin · Paclitaxel

Start the discussion